Litcius/Paper detail

PCN175 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC NON-SMALL CELL LUNG CANCER WITH DIFFERENT PD-L1 EXPRESSION LEVELS IN CHINA USING BOTH PARTITION SURVIVAL AND MARKOV MODELS

Haonan Xu, Aixia Ma

2020Value in Health17 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePembrolizumabOncologyLung cancerCost-effectiveness analysisInternal medicinePopulationDemographyCost effectivenessCancerImmunotherapyEnvironmental healthRisk analysis (engineering)SociologyCancer Immunotherapy and BiomarkersHealth Systems, Economic Evaluations, Quality of LifeEconomic and Financial Impacts of Cancer
PCN175 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC NON-SMALL CELL LUNG CANCER WITH DIFFERENT PD-L1 EXPRESSION LEVELS IN CHINA USING BOTH PARTITION SURVIVAL AND MARKOV MODELS | Litcius